TB-500 Legal Status, FDA 503A Category, and Compounding Access

TB-500 legal status: the current FDA fact

TB-500 legal status starts with one present-tense fact from the FDA record. FDA lists this substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," and placed it in 503A "Category 2" — bulk substances that may present significant safety risks — effective with FDA's September 29, 2023 update to its nominated-substances list, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information ^[16]. As a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding, and it is not an FDA-approved drug ^[16][17].

A short framework note makes that concrete. Under the U.S. Federal Food, Drug, and Cosmetic Act, a compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulk drug substances list; substances not yet listed are evaluated through a public nomination process with input from the Pharmacy Compounding Advisory Committee (PCAC) ^[17]. Category 1 substances are covered by FDA's enforcement-discretion policy while under evaluation; Category 2 substances, identified as raising significant safety risks, are not ^[17]. FDA approval of a finished drug is a separate question from whether a bulk substance may be compounded — and TB-500 is neither approved nor afforded that discretion ^[17].

What is on the FDA calendar for 2026

Access here is under active FDA review, and it may expand in 2026 — anchored on a specific, citable fact. "TB-500 (free base)" and "TB-500 acetate" are individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24, 2026, as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[18]. The same agenda lists BPC-157, KPV and MOTs-C ^[18].

What that fact is, and what it is not, both matter. It is a scheduled evaluation and discussion of a substance under review — a step in the process ^[18]. It is not a listing decision, not a reclassification, and not a change in current status; a PCAC discussion is advisory, and inclusion on a final bulks list is decided by FDA rulemaking ^[17][18]. No outcome should be assumed or dated. As of the FDA record used here, Category 2 remains the last confirmable FDA action for this substance ^[16]. Reports circulating in 2026 of a broader peptide reclassification, or of specific dated removals from Category 2, could not be confirmed from an authoritative FDA source and are not treated as having occurred ^[16].

How legally compounded peptide access is structured

In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[19]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[19].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued — but it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[19]. The ingredient-eligibility caveat is the binding one here: a compounder may use an active ingredient only if it is eligible under the 503A/503B bulk-substance rules, and an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[19]. For TB-500, that status is Category 2 today ^[16]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance.

Is TB-500 FDA approved?

No. TB-500 has no FDA-approved therapeutic indication; it is a research-chemical and veterinary-context substance, not an approved medicine ^[16]. FDA has separately placed the LKKTETQ fragment ("also known as TB-500") in 503A Category 2, meaning it is also not within FDA's enforcement-discretion policy for compounding ^[16]. Approval of a finished drug and eligibility for compounding are distinct questions, and TB-500 satisfies neither today ^[17].

What is the FDA 503A status of TB-500?

FDA placed "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in 503A Category 2 — bulk substances that may present significant safety risks — effective with its September 29, 2023 update, citing potential immunogenicity for certain routes and a lack of important safety information ^[16]. Category 2 substances are not covered by the enforcement-discretion policy that applies to Category 1, so the substance is not eligible for routine 503A compounding while that status stands ^[16][17].

Can you get TB-500 from a compounding pharmacy?

A 503A compounding pharmacy may use a bulk drug substance only if it is eligible under the compounding rules, and FDA has placed TB-500 in Category 2 (significant safety risks), which is not within FDA's enforcement-discretion policy ^[16][17]. While that status stands, the substance is not eligible for routine 503A compounding ^[19]. TB-500 is individually listed on the July 2026 PCAC agenda for evaluation, but that is a scheduled discussion, not a change in status ^[18].

Is TB-500 banned by WADA and in competitive sports?

Yes. TB-500 and thymosin beta-4 fall under WADA-prohibited peptide and growth-factor categories and are banned both in and out of competition for the relevant classes. The substance is detected by LC-MS anti-doping assays in equine and human matrices, and it has been encountered as a designer drug in sport. The WADA status is independent of the FDA compounding question.

Why is TB-500 used in racehorses?

TB-500 was supplied as a veterinary preparation and was encountered as a designer drug in racehorses, which prompted the development of LC-MS anti-doping detection methods for the peptide and its metabolites in equine plasma and urine. The veterinary-context history is part of why the substance sits in a research/veterinary register rather than an approved-human-medicine one ^[16].

Is TB-500 legal?

TB-500 has no FDA-approved indication, is WADA-prohibited, and is classified as a prescription medicine in some jurisdictions (for example Australia and New Zealand); it is sold by research suppliers for laboratory use only ^[16]. "Legal" therefore depends on the jurisdiction and the use: as a U.S. compounding ingredient it sits in 503A Category 2 today, which is not eligible for routine compounding while that status stands ^[16][19].